Sign Up to like & get
recommendations!
1
Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26276
Abstract: Eliglustat, an oral substrate reduction therapy, is approved for eligible adults with Gaucher disease type 1. In the Phase 3 ENGAGE trial of previously untreated adults with Gaucher disease type 1, eliglustat‐treated patients had statistically…
read more here.
Keywords:
disease type;
engage trial;
gaucher disease;
disease ... See more keywords